Evaluation of Epstein-Barr virus antigen-based immunoassays for serological diagnosis of nasopharyngeal carcinoma |
| |
| Institution: | 1. Department of Microbiology, Division of Otorhinolaryngology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, Hong Kong;2. EUROIMMUN AG, Seekamp 31, D 23560 Lübeck, Germany;3. Division of Otorhinolaryngology, Department of Surgery, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, Hong Kong;4. Department of Anatomical Cellular Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, Hong Kong;5. Centre for Emerging Infectious Diseases, School of Public Health, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong SAR, Hong Kong;1. Department of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN;2. Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN;1. Department of Gastroenterological Surgery, National Kyushu Cancer Center, Fukuoka, Japan;2. Department of Surgery, Tagawa Municipal Hospital, Fukuoka, Japan;3. Department of Surgery, Matsuyama Red Cross Hospital, Ehime, Japan;1. National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India;2. National Institute for Research in Tuberculosis (NIRT), Chennai, India;3. Government Stanley Medical Hospital, Chennai, India;4. Laboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA |
| |
| Abstract: | BackgroundImmunofluorescence (IF) assays based on Epstein-Barr virus (EBV)-encoded antigens have traditionally been the preferred approach for serological screening of nasopharyngeal carcinoma (NPC).ObjectivesTo compare the performance of two new commercial assays (indicated by COMM) using, respectively, the IF and enzyme-linked immunosorbent assay (ELISA) formats with an in-house IF assay (IFA).Study designSera from 163 patients with histologically confirmed NPC, and 98 healthy controls were tested with each of these assays and their results compared.ResultsThe sensitivity, specificity, positive and negative predictive values, respectively, for the COMM VCA IgA ELISA were 92.6%, 94.9%, 96.8%, 88.6%; for the COMM VCA IgA IFA were 96.9%, 41.8%, 73.5%, 89.1%; for the in-house VCA IgA IFA were 98.2%, 72.4%, 85.6%, 95.9%; for the COMM EA IgA ELISA were 46.6%, 100%, 100%, 53.0%; for the COMM EA IgA IFA were 77.3%, 100%, 100%, 72.6%; and for the in-house EA IgA IFA were 77.9%, 99.0%, 99.2%, 72.9%.ConclusionsThe receiver operating characteristic curves comparison showed a marginal superior accuracy for the COMM VCA IgA ELISA, suggesting this to be used as a high-throughput serological screening assay, with the more specific COMM EA IgA IFA as a follow-up confirmatory assay in this NPC-endemic area. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
